CIMT 2018 Annual Meeting

Mainz, May 15-17, 2018 – CIMT 2018 Annual Meeting

We are excited about the upcoming Annual Meeting of the Association for Cancer Immunotherapy (CIMT) in our hometown Mainz. Our scientists will be presenting their research in several sessions and look forward to discussing their projects.

Thursday, 17 May 2018, Short Talk Session IV Therapeutic Vaccination

  • Local radiotherapy and E7-RNA-LPX vaccination activate non-redundant mechanisms and lead to complete tumor rejection of well-established HPV16+ TC-1 tumors (Nadja Salomon)

TRON Posters:

  • Retrospective analysis of neoantigen prediction methods (Abstract 018, Martin Löwer)
  • Local radiotherapy and E7-RNA-LPX vaccination activate non-redundant mechanisms and lead to complete tumor rejection of well-established HPV16+ TC-1 tumors (Abstract 027, Nadja Salomon)
  • A two chain chimeric antigen receptor (CAR) scaffold recruits T-cell endogenous CD3 subunits for physiological CAR signaling and induces efficient tumor cell killing in vitro and in vivo (Abstract 167, Matthias Birtel, Ralf-Holger Voss)

Active collaborations:

  • The Glioma Actively Personalized Vaccine Consortium (GAPVAC) presents the successful clinical translation of mutated peptide vaccination (Abstract 005)
  • Successful completion of the Mutanome Engineered RNA Immuno-Therapy (MERIT) project (Abstract 010)
  • E6/E7 RNA(LIP): An RNA cancer vaccine for treatment of patients with HPV16-positive malignancies (Abstract 012)
  • A first-in-human phase I/II clinical trial assessing novel mRNA-lipoplex nanoparticles encoding shared tumor antigens for immunotherapy of malignant melanoma (Abstract 014)

http://www.meeting.cimt.eu/